Posts

Northwell Health Adopts Clinithink Technology to Accelerate Patient Identification for Clinical Trials

Clinithink’s CLiX is now implemented and showing significant improvement in identifying candidates for clinical trials and research at one of the largest health systems in the US.

 

Northwell Health is far more than a health system. A phenomenal centre of talent and excellence the organization cares for a service area of eight million people, across 23 hospitals and more than 700 outpatient locations. Northwell has 68,000 employees, including more than 30,000 physicians and nurses operating across a huge range of specialties.

 

Northwell is also the home of The Feinstein Institute for Medical Research – a collaboration of creative thinkers who share a singular focus of advancing science to prevent disease and cure patients. Northwell’s overarching focus is on changing healthcare – not just by discovering the latest medical and scientific advancements, or by training the doctors of tomorrow, but by adopting innovative new software like CLiX to reinvent their approach to clinical research.

 

Serving one of the most diverse patient populations in the US, Northwell Health has been quick to recognise that the adoption of AI and NLP technologies like CLiX could reinvent the clinical trial feasibility model – enabling the rapid identification of potential patients for clinical trial that had simply been missed before.

 

And CLiX is now providing the deepest, fastest and most accurate analysis of unstructured patient data ever seen at Northwell – successfully identifying candidates for clinical trials in hours not months.

 

In a proof of concept study of COPD at Northwell the total patient cohort considered was 939,378 patients and there were 3.3 million associated documents for review. CLiX assessed these patients against 22 individual criteria in just 30 hours – a fraction of the time it would have taken previously – producing an impressive 88 patients to review, all of whom were highly relevant to the trial.

 

Elaine Brennan, Managing Director of Pharma Ventures at Northwell Health, said:  “What is really exciting about working with CLiX ENRICH is that it allows us to mine a much richer data set and identify potential patients across our entire network, not just the specific location where the study is being conducted.  Leveraging tools to support the patient identification and enrollment process is part of Northwell’s strategic goals to make clinical trials an option for patients and to make Northwell a premier destination for clinical trials.”

 

What’s more, CLiX ENRICH has been easy to adopt at Northwell Health. The software effortlessly drills down to a granular level, that has only previously been possible by manual review, thereby dramatically speeding up the decision making process for the reviewer. In addition, as ENRICHed Lists focus pre-screening on those patients most likely to qualify for the clinical trial, Northwell has found that they have eliminated the ‘data noise’ they often experienced previously.

 

Sarah Beeby, EVP, GM Life Sciences for Clinithink said:  “Northwell Health is a superb addition to Clinithink’s network. The strategic alliance between ourselves and Northwell recognises that narrative clinical data is a huge untapped asset for health systems around the world, and the fact that our technology enables Northwell to really leverage the breadth and depth of their immensely diverse patient population to rapidly identify potential patients for trial is a fact we are very proud of indeed.”

 

For further information on Clinithink’s work with Northwell, or on what CLiX ENRICH software can do for your clinical trials, please contact marc.horowitz@clinithink.com

 

About Clinithink 

Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. It enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most.  And it can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing – helping our life science associates get the treatments patients need to market faster. For further information visit clinithink.com

 

About Northwell Health

Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, more than 700 outpatient facilities and more than 13,600 affiliated physicians. Northwell cares for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from Northwell’s communities. Northwell’s 68,000 employees – 16,000-plus nurses and 4,000 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. They are making breakthroughs in medicine at the Feinstein Institute for Medical Research. They are training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and at the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. For further information visit Northwell.edu.

 

– Ends –

 

FOR MEDIA INFORMATION: Sarah Roberts, Vane Percy & Roberts, (T) +44 (0) 1737 821890; (E) sarah@vanepercy.com

Newcastle Hospitals Improve Patient Recruitment with CLiX Software

Following the successful conclusion of a pilot study, Clinithink’s CLiX software is now being used by the Newcastle upon Tyne Hospitals NHS Foundation Trust – one of the UK’s leading clinical research centres – to improve patient recruitment in their clinical trials.

A strong, collaborative relationship has been established between Clinithink and the Newcastle Hospitals and, as CLiX has made Newcastle a more attractive clinical research site thanks to its improved patient recruitment capabilities, Newcastle is now looking to expand its use of Clinithink’s CLiX software into its non-commercial trial space too.

Professor Julia Newton, Deputy Medical Director of Newcastle upon Tyne Hospitals said: “Working with Clinithink has changed how we deliver commercial work.  We have topped the NIHR league tables for research for seven consecutive years now, we are proud of how we deliver to time and target, and we are always looking for ways to work better and more efficiently. Clinithink represents such innovation for us.”

Challenge & Solution

Just like the rest of the clinical trials industry Newcastle had, in the past, suffered from recruitment challenges. The institution knew all too well that more than three-quarters of all clinical trials experience delay, with the daily bill for this delay being somewhere between $600,000 and $8m. Awareness of this, coupled with a desire to increase its commercial research activity, drove Newcastle to seek out a solution that would identify the appropriate patients for clinical trial recruitment more effectively.

And Clinithink’s patented CLiX natural language processing (NLP) platform is that solution. It uses market-leading artificial intelligence (AI) technology to accurately ‘read’ and interpret up to two million clinical documents an hour, automating the review of a hospital’s clinical notes and connecting physicians and patients with suitable clinical trials.

CLiX has also been proven to dramatically reduce the time and investment currently required to find and enrol patients into clinical trials. By quickly and efficiently processing existing unstructured patient data, sites are able to identify eligible subjects against trial-specific inclusion and exclusion criteria up to 20 times faster than by reviewing patient data manually.

Prior to the use of CLiX ENRICH, the Newcastle research team had spent three years manually reviewing over 2000 patients, identifying 30 potentially eligible candidates during that time. But with CLiX ENRICH on board the team was able to process the records of 270,000 patients in less than 24 hours providing a shortlist of 100 potentially eligible patients in a fraction of the previous time.

What’s more, this success has led not only to Clinithink’s software being embedded into Newcastle’s data warehouse but also into Newcastle’s recently completed Phase III Trial Unit.

Professor Yan Yiannakou, Director of the Phase III Unit for the Newcastle Hospitals, said:  “This is a genuinely intelligent system which is not dependent on coding – it actually reads the health record, producing eligibility lists which are always accurate.  Our innovative P3 Clinical Research Unit is open for business and using Clinithink software because we know it works.”

Next Steps

So what’s next for Clinithink and Newcastle? The partners are looking to work with more NHS Trusts in and around Newcastle to expand the amount of patient data available and to further increase the number of potentially suitable patients identified for clinical trials. On an even wider scale, the NHS has announced its intention to replicate the model of Newcastle’s Phase 3 unit (with CLiX as an inherent part of that model) across five other regional trusts across the UK.

Sarah Beeby, EVP, GM Life Sciences, Clinithink said: “We are extremely proud to be working with such a dynamic Trust and the collaboration between Clinithink and Newcastle continues to inspire and excite us. We very much look forward to the next steps in our mission to deliver patient insights for everyone.”

For further information, visit http://www.clinithink.com

Or email sarah@vanepercy.com for press enquiries

Clinithink secures growth-equity investment to fuel growth

Leading healthcare technology investors partner with Clinithink to unlock the potential of unstructured data to inform treatment decisions, identify candidates for clinical trials, and ensure appropriate reimbursement

 

Clinithink, which offers healthcare and life sciences organizations powerful clinical data insights through its patented CLiX natural language processing (NLP) platform, has secured a growth-equity investment from TT Capital Partners (TTCP) and the MSD Global Health Innovation Fund (GHI) to expand its global footprint and continue to broaden its service offering.

 

Clinithink CEO, Dr Chris Tackaberry said: “We are delighted to have been able to close this latest round of funding with TTCP and MSD GHI. Not only because it enables us to expedite our growth but, strategically, we now have two further partners whose business is all about innovation.”

 

Narrative clinical patient data is a valuable asset in healthcare that has historically been inaccessible due to its lack of structure and the reliance on structured data and key word searches to interpret and understand this information. Clinithink’s CLiX technology uses market-leading artificial intelligence (AI) technology to accurately ‘read’ and interpret up to two million clinical documents an hour, impacting patient care across the healthcare continuum:

 

  • Precision medicine: Evidence suggests that phenotype is at least as important as genotype in diagnosis and the development of new treatments. Clinithink compares a patient’s extracted phenotype with over 12,000 phenotypes and over 15,000 synonyms describing the characteristics of thousands of rare diseases. Recently, Clinithink was part of a collaboration which achieved a GUINNESS WORLD RECORDS™ title for the fastest genetic diagnosis. The project successfully compressed the time needed to diagnose rare genetic disorders in newborns through DNA sequencing and phenotype analysis to 19.5 hours in a seamless end-to-end process. Clinithink participated in this exciting project with Rady Children’s Institute of Genomic Medicine (RCIGM), San Diego, California and its partners. This work also received a RARE Champion of Hope award from Global Genes® recognizing the contribution to rare disease diagnosis.
  • Patient matching for clinical trials and Real World Evidence (RWE) studies: An estimated 85% of all clinical trials will experience delays, with 94% being delayed by over a month. The financial impact can be massive, costing between $600,000 – $8 million every day. Many delays are caused because sites struggle to find and recruit patients. Clinithink automates the review of a hospital’s clinical notes and connects physicians and patients with clinical trials. Clinithink also helps leading biopharma and contract research organizations (CROs) with site selection and protocol optimization in order to accelerate drug development and get promising new therapies to patients by leveraging its solution to support real world data analysis.
  • Revenue cycle management (RCM): RCM is estimated to be a $90 billion market by 2022, representing the growing importance of capabilities that help optimize the healthcare system. Clinithink provides revenue cycle management capabilities to help hospitals and health systems review clinical documents to verify the appropriateness of diagnostic tests and treatments, while ensuring appropriate reimbursement.

 

“Clinithink has a proven track record of turning data and information into actionable insight for its biopharma and healthcare provider customers,” said Conor Green, Partner at TT Capital Partners. “We look forward to collaborating with Clinithink’s world-class team as they continue to improve the lives of patients around the world.”

 

“The ability to capture meaningful information from narrative clinical data across the healthcare spectrum is critical to driving innovation.” added Prem Tumkosit, Investment Principal at MSD Global Health Innovation Fund LLC, “We believe these capabilities have the potential to make a major contribution to changing the way healthcare is delivered.”

 

 

About Clinithink

Clinithink: Every patient, precisely

 

Clinithink’s platform delivers the deepest, fastest and most accurate analysis of unstructured data across patient populations currently possible. This analysis provides medical professionals with the knowledge they need to quickly and accurately diagnose conditions and plan the most effective treatments. Which enables our healthcare partners to provide optimal care to patients that is swiftly reimbursed, protecting their ability to deliver care to the people who need it most. This analysis can also fast forward drug development; ensuring protocols are optimized, patients matched and sites identified in a fraction of the time of manual processing. This helps our life sciences associates get the treatments patients need to market faster.

 

For more, visit http://www.clinithink.com

 

About TT Capital Partners

TT Capital Partners (TTCP) is the principal investing arm of the TripleTree platform, a healthcare merchant bank. TTCP collaborates with healthcare technology and services companies that have the potential to become market leaders.  Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth businesses in healthcare. For more, visit www.ttcapitalpartners.com.

 

About MSD Global Health Innovation Fund

MSD Global Health Innovation Fund (GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.  This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions. With a vision that data will be the currency in healthcare, GHI invests broadly in digital health.  GHI invests in platform companies with proven technologies or business models where MSD’s expertise and perspectives can accelerate revenue growth and enhance value creation.  For more, visit www.msdghifund.com

 

Clinithink receives RARE Champion of Hope award for their ‘notable efforts’ in rare disease

Clinithink has been selected to receive the RARE Champion of Hope – Collaborations in Science and Technology award at the 7th Annual RARE Patient Advocacy Summit on October 4th in Irvine, California.

 

Over 200 individuals and organizations worldwide were nominated by their peers for a RARE Champion of Hope award for their notable efforts in rare disease advocacy, teen advocacy, science, medical care and treatment and collaborations.

 

Along with their collaborators Rady Children’s Institute for Genomic Medicine and Alexion Pharmaceuticals, Clinithink was selected to receive the award because of the work which resulted in the successful compression of the time needed to diagnose rare genetic disorders in newborns through DNA sequencing to 19.5 hours.

 

Clinithink’s CLiX solution has been shown to dramatically accelerate the diagnosis of rare disease. This was evidenced in the Rady-Alexion-Clinithink collaboration, for which the RARE Champion of Hope has been awarded, where Clinithink’s NLP solution was used for two key activities in the process:

  1. quickly combing through electronic medical records to extract crucial phenotype information
  2. comparing the extracted phenotype with over 12,000 phenotypes (plus an additional 15,000 synonyms) describing the characteristics of thousands of rare diseases.

 

The Clinithink solution can perform both of these tasks in seconds compared to the hours or days it would take a highly skilled specialist physician to do.

 

The diagnosis of rare disease is incredibly challenging and, if left undiagnosed these conditions are very expensive to manage and, often, life limiting. Genomics data has held great promise and, increasingly, evidence is suggesting that phenotype is at least as important as genotype in diagnosis and the development of new treatments. However, in order to be able to unlock the true value of such data AI tools, such as Clinithink’s patented CLiX Natural language processing (NLP) solution is essential.

 

Sarah Beeby SVP, Life Sciences said: “Our work with Rady and Alexion has enabled us to evidence the value of our technology and, more importantly, be involved in projects that can help save the lives of those with rare diseases.

 

“Narrative data is a valuable asset in healthcare but is largely inaccessible due to its lack of structure as existing technologies rely on structured data or key word searches. Our CLiX technology can ‘read’ thousands of clinical documents an hour and extract the information they contain. This has significant benefit in the clinical setting and is also very powerful for clinical trials as it can optimize the development process along the entire continuum.”

 

Clinithink CEO, Dr Chris Tackaberry said: “We are absolutely delighted to be recognised together with our collaborators in the RARE Champion of Hope awards and very much look forward to meeting colleagues and peers involved in this exciting space at the RARE Patient Advocacy Summit in October.”

 

http://www.clinithink.com